CSPC Pharmaceutical Group Limited Capital Reinvestment Ratio
CSPC Pharmaceutical Group Limited capital reinvestment ratio. CSPC Pharmaceutical Group Limited (CVG) has a Capital Reinvestment Ratio of 0.12x as of September 2020, meaning it reinvests 0% of its operating cash flow (€2.16 Billion) in capital expenditures (€258.14 Million). Check CSPC Pharmaceutical Group Limited total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of CSPC Pharmaceutical Group Limited (2013–2025)
Capital reinvestment ratio of CSPC Pharmaceutical Group Limited from 2013 to 2025. This chart tracks CSPC Pharmaceutical Group Limited's Capital Reinvestment Ratio across 13 annual periods. Also explore CSPC Pharmaceutical Group Limited (CVG) net asset momentum to track the company's year-over-year net asset growth rate.
CSPC Pharmaceutical Group Limited Capital Reinvestment Ratio by Year (2013–2025)
CSPC Pharmaceutical Group Limited capital reinvestment ratio by year from 2013 to 2025. For the full cash flow conversion analysis, see CVG operating cash flow.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | €5.83 Billion | €2.28 Billion | ▼ -33.8% |
| 2024 | 0.59x | €4.53 Billion | €2.68 Billion | ▲ +30.4% |
| 2023 | 0.45x | €4.18 Billion | €1.89 Billion | ▲ +55.6% |
| 2022 | 0.29x | €7.63 Billion | €2.22 Billion | ▼ -4.3% |
| 2021 | 0.30x | €4.64 Billion | €1.41 Billion | ▲ +51.1% |
| 2020 | 0.20x | €6.74 Billion | €1.36 Billion | ▼ -59.6% |
| 2019 | 0.50x | €3.78 Billion | €1.88 Billion | ▲ +13.3% |
| 2018 | 0.44x | €3.80 Billion | €1.67 Billion | ▲ +22.6% |
| 2017 | 0.36x | €3.29 Billion | €1.18 Billion | ▼ -1.7% |
| 2016 | 0.36x | €2.92 Billion | €1.06 Billion | ▲ +0.4% |
| 2015 | 0.36x | €2.25 Billion | €815.69 Million | ▼ -18.8% |
| 2014 | 0.45x | €1.81 Billion | €807.00 Million | ▼ -39.0% |
| 2013 | 0.73x | €814.86 Million | €597.12 Million | — |